Eikon Therapeutics

Organisation

Trials

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Phase 2/3, Recruiting, 750 people, 26 Jan 2026
NCT06246110
Phase 2, Active, not recruiting, 70 people, 7 Feb 2024

Sources: clinicaltrials.gov

Named in competing interests

Pan-Epigenetic Age Prediction in Mammals
Consulting or advice, Shares or equity, 1 Feb 2026

Sources: pubmed.ncbi.nlm.nih.gov